A detailed history of China Universal Asset Management Co., Ltd. transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 6,713 shares of RAPT stock, worth $8,592. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,713
Previous 4,101 63.69%
Holding current value
$8,592
Previous $12,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$1.76 - $3.75 $4,597 - $9,795
2,612 Added 63.69%
6,713 $13,000
Q2 2024

Jul 19, 2024

SELL
$2.89 - $9.38 $7,227 - $23,459
-2,501 Reduced 37.88%
4,101 $12,000
Q1 2024

Apr 29, 2024

BUY
$6.87 - $26.45 $18,006 - $69,325
2,621 Added 65.84%
6,602 $59,000
Q4 2023

May 21, 2024

SELL
$11.28 - $25.46 $29,564 - $66,730
-2,621 Reduced 39.7%
3,981 $98,000
Q4 2023

Jan 23, 2024

BUY
$11.28 - $25.46 $34,877 - $78,722
3,092 Added 347.81%
3,981 $99,000
Q3 2023

May 21, 2024

BUY
$16.34 - $24.66 $7,173 - $10,825
439 Added 97.56%
889 $14,000
Q3 2023

Oct 30, 2023

BUY
$16.34 - $24.66 $7,173 - $10,825
439 Added 97.56%
889 $15,000
Q2 2023

May 21, 2024

SELL
$16.06 - $21.61 $160 - $216
-10 Reduced 2.17%
450 $8,000
Q2 2023

Jul 27, 2023

SELL
$16.06 - $21.61 $160 - $216
-10 Reduced 2.17%
450 $8,000
Q1 2023

May 21, 2024

BUY
$17.19 - $30.8 $1,976 - $3,542
115 Added 33.33%
460 $8,000
Q1 2023

Apr 27, 2023

BUY
$17.19 - $30.8 $1,976 - $3,542
115 Added 33.33%
460 $8,000
Q4 2022

May 21, 2024

SELL
$16.28 - $24.6 $101,863 - $153,922
-6,257 Reduced 94.77%
345 $6,000
Q4 2022

Jan 31, 2023

BUY
$16.28 - $24.6 $1,090 - $1,648
67 Added 24.1%
345 $7,000
Q3 2022

Oct 21, 2022

BUY
$17.96 - $30.46 $4,992 - $8,467
278 New
278 $7,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $38M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.